Skip to main content

Table 1 Demographic and clinical characteristics of study patients

From: Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

  Gemcitabine +
Erlotinib
(100 mg QD)
Motesanib + Gemcitabine + Erlotinib
(100 mg QD)
Motesanib + Erlotinib
(150 mg QD)
Characteristic Control
(n = 8)
Motesanib
50 mg QD
(n = 7)
Motesanib
100 mg QD
(n = 8)
Motesanib
125 mg QD
(n = 10)
Motesanib
75 mg BID
(n = 9)
Motesanib
100 mg QD
(n = 7)
Motesanib
125 mg QD
(n = 7)
Sex, n        
   Women 3 6 3 5 7 7 2
   Men 5 1 5 5 2 0 5
Race, n        
   White 7 7 6 10 6 6 7
   Asian 0 0 2 0 3 1 0
   Japanese 1 0 0 0 0 0 0
Median age, y (range) 62 (36-71) 66 (46-80) 50 (40-75) 59.5 (36-77) 53 (21-76) 50 (35-76) 55 (46-73)
ECOG performance status, n        
   0 3 1 5 4 4 5 5
   1 5 5 3 5 5 2 2
   2 0 1 0 1 0 0 0
Disease stage, n        
   I 0 0 0 1 0 0 0
   II 0 0 0 1 0 0 1
   III 0 0 1 0 1 0 0
   IV 8 7 7 8 8 7 6
Tumor type, n        
   Colon 3 0 1 1 1 1 0
   Pancreatic 1 1 0 1 0 0 2
   Breast 0 0 1 0 0 2 1
   Melanoma 0 0 1 1 1 0 0
   Non—small        
cell lung 0 1 1 0 1 0 0
   Squamous cell        
head/neck 0 1 1 0 0 1 0
   Medullary        
thyroid 0 0 1 1 0 0 1
   Carcinoma        
unknown        
origin 1 0 0 1 0 0 0
   Ovarian 0 1 0 0 1 0 0
   Prostate 0 0 0 0 0 0 2
   Stomach 0 1 0 0 1 0 0
   Othera 3 2 2 5 4 3 1
Prior therapy, nb        
   0 3 1 0 6 2 1 1
   1 to 2 1 2 3 1 4 1 1
   3 to 4 1 2 2 1 0 1 3
   ≥ 5 3 2 3 2 3 4 2
Prior chemotherapy, n        
   0 3 2 2 8 2 1 1
   1 to 2 1 3 3 1 4 2 3
   3 to 4 1 1 2 1 1 1 1
   ≥ 5 3 1 1 0 2 3 2
Prior radiotherapy, n        
   0 5 3 3 6 5 5 4
   1 to 2 3 3 3 3 3 1 2
   3 to 4 0 1 2 0 1 1 1
   ≥ 5 0 0 0 1 0 0 0
  1. BID = twice daily; ECOG = Eastern Cooperative Oncology Group; QD = once daily
  2. aIncludes tumor types occurring in ≤ 2% of patients.
  3. bAll cancer therapies patients received before study enrollment.